title: Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
abstract: Rheumatoid arthritis (RA) is a complex, systemic autoimmune disease characterized by chronic inflammation of multiple peripheral joints, which leads to serious destruction of cartilage and bone, progressive deformity and severe disability. Methotrexate (MTX) is one of the first-line drugs commonly used in RA therapy owing to its excellent long-term efficacy and cheapness. However, the efficacy and toxicity of MTX treatment have significant interpatient variability. Genetic factors contribute to this variability. In this review, we have summarized and updated the progress of RA response to MTX treatment since 2009 by focusing on the fields of pharmacogenetics and pharmacogenomics. Identification of genetic factors involved in MTX treatment response will increase the understanding of RA pathology and the development of new personalized treatments.
authors.affiliation: Center for Genetic Epidemiology & Genomics, School of Public Health, Soochow University, Suzhou, Jiangsu 215123, PR China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zhu
authors.forename: Fei-Yan
authors.initials: FY
authors.lastname: Deng
authors.forename: Xing-Bo
authors.initials: XB
authors.lastname: Mo
authors.forename: Ying-Hua
authors.initials: YH
authors.lastname: Qiu
authors.forename: Shu-Feng
authors.initials: SF
authors.lastname: Lei
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D010597:Pharmacogenetics / Q000379:methods; D011110:Polymorphism, Genetic / Q000235:genetics
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate